Anticancer agent, pharmaceutical composition for cancer treatment, kit, and activator
AssigneesBioComo Incorporation, Mie University
InventorsMasayuki FUKUMURA, Junpei OHTSUKA, Yasuhisa MATSUKAWA, Tetsuya NOSAKA, Tomomi OHTSUKA
Life of this patent
Estimating the term…
Abstract
An anticancer agent for solid cancer contains, as an active ingredient, human parainfluenza virus type 2 expressing: at least one kind of cytokine selected from the group consisting of IL-2, IL-7, IL-12, IL-15, and IL-18; or a combination of the cytokine and CCL19 and/or CCL21; or a mutant of either the cytokine or the combination, the mutant having the same function.
Claims13
An anticancer agent for solid cancer, comprising, as an active ingredient, human parainfluenza virus type 2 expressing:
- at least one cytokine selected from the group consisting of IL-2, IL-7, IL-12, IL-15, and IL-18;
- or
- a combination of the at least one cytokine and CCL19 and/or CCL21;
- or
- a mutant of either the at least one cytokine or the combination, the mutant having the same function.
A kit for use in treatment of solid cancer, the kit comprising, for simultaneous use or sequential use in the treatment:
- human parainfluenza virus type 2 expressing at least one cytokine selected from the group consisting of IL-2, IL-7, IL-12, IL-15, and IL-18, or a combination of the at least one cytokine and CCL19 and/or CCL21, or a mutant of either the at least one cytokine or the combination, the mutant having the same function;
- and
- an immune activator and/or an immune checkpoint inhibitor.
A tumor-infiltrating T cell and dendritic cell activator, comprising, as an active ingredient:
- human parainfluenza virus type 2 expressing at least one cytokine selected from the group consisting of IL-2, IL-7, IL-12, IL-15, and IL-18;
- or a combination of the at least one cytokine and CCL19 and/or CCL21;
- or a mutant of either the at least one cytokine or the combination, the mutant having the same function.
Dependencies are inferred from the claim text.